Inspire Investing LLC Makes New Investment in Ironwood Pharmaceuticals, Inc. $IRWD

Inspire Investing LLC purchased a new position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 509,941 shares of the biotechnology company’s stock, valued at approximately $1,790,000. Inspire Investing LLC owned approximately 0.31% of Ironwood Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of the business. Range Financial Group LLC bought a new position in Ironwood Pharmaceuticals in the 4th quarter valued at about $1,436,000. Hillsdale Investment Management Inc. bought a new stake in shares of Ironwood Pharmaceuticals during the 4th quarter worth about $3,897,000. GSA Capital Partners LLP lifted its stake in shares of Ironwood Pharmaceuticals by 84.7% in the 4th quarter. GSA Capital Partners LLP now owns 571,613 shares of the biotechnology company’s stock worth $1,926,000 after acquiring an additional 262,084 shares during the period. Persistent Asset Partners Ltd bought a new position in shares of Ironwood Pharmaceuticals in the fourth quarter valued at approximately $613,000. Finally, WINTON GROUP Ltd acquired a new position in shares of Ironwood Pharmaceuticals during the fourth quarter valued at approximately $554,000.

Insider Activity at Ironwood Pharmaceuticals

In other news, Director Julie Mchugh sold 21,571 shares of Ironwood Pharmaceuticals stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $3.73, for a total value of $80,459.83. Following the transaction, the director directly owned 250,749 shares of the company’s stock, valued at $935,293.77. This trade represents a 7.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 9.30% of the stock is currently owned by insiders.

Ironwood Pharmaceuticals Stock Down 2.1%

IRWD opened at $4.21 on Wednesday. The firm has a market cap of $686.48 million, a PE ratio of 7.02 and a beta of 0.25. The business has a fifty day simple moving average of $3.83 and a 200-day simple moving average of $3.90. Ironwood Pharmaceuticals, Inc. has a fifty-two week low of $0.67 and a fifty-two week high of $5.78.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its earnings results on Thursday, May 7th. The biotechnology company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.01). Ironwood Pharmaceuticals had a net margin of 28.26% and a negative return on equity of 39.65%. The company had revenue of $106.51 million for the quarter, compared to analysts’ expectations of $92.11 million. On average, equities research analysts anticipate that Ironwood Pharmaceuticals, Inc. will post 1.04 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Wall Street Zen raised Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Sunday, May 17th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Ironwood Pharmaceuticals in a research note on Monday, April 27th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $6.23.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.